DE60329668D1 - Verfahren zur unterdrückung der ptx3 genexpression - Google Patents

Verfahren zur unterdrückung der ptx3 genexpression

Info

Publication number
DE60329668D1
DE60329668D1 DE60329668T DE60329668T DE60329668D1 DE 60329668 D1 DE60329668 D1 DE 60329668D1 DE 60329668 T DE60329668 T DE 60329668T DE 60329668 T DE60329668 T DE 60329668T DE 60329668 D1 DE60329668 D1 DE 60329668D1
Authority
DE
Germany
Prior art keywords
sup
sub
suppressing
gene expression
ptx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329668T
Other languages
German (de)
English (en)
Inventor
Shigeru Morikawa
Akashi Izumi
Takao Hamakubo
Tatsuhiko Kodama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nissan Chemical Corp
Original Assignee
Kowa Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Nissan Chemical Corp filed Critical Kowa Co Ltd
Application granted granted Critical
Publication of DE60329668D1 publication Critical patent/DE60329668D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE60329668T 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression Expired - Lifetime DE60329668D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37211402P 2002-04-15 2002-04-15
US10/196,428 US20030195167A1 (en) 2002-04-15 2002-07-17 PTX3-gene expression inhibitor
PCT/JP2003/004603 WO2003086380A1 (en) 2002-04-15 2003-04-11 Ptx3 gene expression suppressing method

Publications (1)

Publication Number Publication Date
DE60329668D1 true DE60329668D1 (de) 2009-11-26

Family

ID=28794074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329668T Expired - Lifetime DE60329668D1 (de) 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression

Country Status (9)

Country Link
US (2) US20030195167A1 (enExample)
EP (1) EP1494661B1 (enExample)
JP (1) JP4409295B2 (enExample)
AT (1) ATE445395T1 (enExample)
AU (1) AU2003226456A1 (enExample)
DE (1) DE60329668D1 (enExample)
MY (1) MY137134A (enExample)
TW (1) TWI349547B (enExample)
WO (1) WO2003086380A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276486A1 (en) * 2003-04-17 2006-12-07 Kowa Co., Ktd. Lklf/klf2 gene expression promoter
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
JP4667372B2 (ja) * 2004-02-25 2011-04-13 株式会社ペルセウスプロテオミクス 血管障害の程度の判定方法
AU2005237543B2 (en) * 2004-04-26 2011-02-10 Alcon, Inc. Statins for the treatment of ocular hypertension and glaucoma
WO2008001499A1 (en) * 2006-06-29 2008-01-03 Kowa Co., Ltd. Prophylactic and/or therapeutic agent for rheumatoid arthritis
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
CA2365869A1 (en) * 1999-03-08 2000-09-14 Richard D. Tillyer Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
AU2001232245A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Tnf- alpha inhibitors
US20020156122A1 (en) * 2000-09-19 2002-10-24 Novlmmune S.A. Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20020159974A1 (en) * 2000-09-19 2002-10-31 Francois Mach Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors)

Also Published As

Publication number Publication date
EP1494661B1 (en) 2009-10-14
TW200403990A (en) 2004-03-16
JP4409295B2 (ja) 2010-02-03
JP2005522490A (ja) 2005-07-28
US20080161348A1 (en) 2008-07-03
ATE445395T1 (de) 2009-10-15
AU2003226456A1 (en) 2003-10-27
US20030195167A1 (en) 2003-10-16
WO2003086380A1 (en) 2003-10-23
AU2003226456A8 (en) 2003-10-27
MY137134A (en) 2008-12-31
TWI349547B (en) 2011-10-01
EP1494661A1 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
TW200519088A (en) Aryl or heteroaryl amide compounds
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
NO20055337L (no) Imidazolinkorrosjonsinhibitorer
ATE201687T1 (de) Galanthamin-derivat, ein verfahren zu seiner herstellung und seine verwendung als medikament
ATE402185T1 (de) Verfahren für fluorcytidinderivate
ATE377593T1 (de) 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung
DE60329668D1 (de) Verfahren zur unterdrückung der ptx3 genexpression
ATE207055T1 (de) Verfahren zur herstellung von 4-aryl-3- hydroxymethyl-piperidinen
NO20062656L (no) Fremgangsmate for fremstilling av statiner
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
PL235835A1 (enExample)
ATE239701T1 (de) Polyethoxylierte retinamid-derivate und verfahren zu ihrer herstellung
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
ATE372332T1 (de) Verfahren zur herstellung von zwischenverbindungen in der herstellung von discodermolid und discodermolid-analoga
DE602004013365D1 (de) Verfahren zur modifizierung eines fluorpolymersubstrats und dadurch erhaltene verbundgegenstände
MXPA05013981A (es) Resolucion de derivados de acido a- (fenoxi) fenilacetico.
ATE447728T1 (de) Lichtempfindliche verbindung und lichtempfindliches harz
DE60314167D1 (de) Verfahren zur herstellung von fluorhalogenalkanen
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
DE602004020050D1 (de) Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
ATE168982T1 (de) Neues verfahren zur herstellung von beta- alkoxyacrylsäure
BRPI0412505A (pt) processo para preparar organohidrogensiloxanos cìclicos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition